Intravenous Solutions Market Report 2026

The intravenous solutions market size has grown strongly in recent years. It will grow from $14.91 billion in 2025 to $16.05 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to growth in hospital admissions and surgical procedures, widespread use of iv fluids for dehydration management, increasing prevalence of chronic diseases, established role of iv therapy in critical care, rising use of electrolyte and glucose solutions.

The intravenous solutions market size is expected to see strong growth in the next few years. It will grow to $21.73 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to expansion of home healthcare and outpatient infusion services, increasing aging population requiring nutritional support, rising adoption of personalized nutrition therapies, advancements in sterile packaging technologies, growing demand for long-term parenteral nutrition. Major trends in the forecast period include rising demand for intravenous hydration in acute and chronic care, increasing use of parenteral nutrition in critical and geriatric care, growing preference for ready-to-use iv solution formulations, expansion of home-based iv therapy and infusion services, increasing focus on sterility and safety in iv solution manufacturing.

The rising incidence of cancer is expected to drive the growth of the intravenous solutions market in the coming years. Cancer comprises a group of diseases marked by uncontrolled cell proliferation, with the potential to invade nearby tissues and spread to other parts of the body. Intravenous solutions are widely used in cancer care to administer chemotherapy drugs and ensure proper hydration during treatment. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that by 2050, more than 35 million new cancer cases were projected, reflecting a 77% increase from the estimated 20 million cases in 2022. Consequently, the rising incidence of cancer is fueling the expansion of the intravenous solutions market.

The rising number of surgical procedures is expected to drive the growth of the intravenous solutions market in the coming years. Surgical procedures are medical interventions performed to treat various diseases and conditions through incisions or other invasive methods. Intravenous solutions play a crucial role in surgical procedures by providing essential support for hydration, electrolyte balance, medication delivery, and emergency care. For example, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional organization representing board-certified aesthetic plastic surgeons, reported that total surgical and non-surgical aesthetic procedures increased by 3.4% in 2023, reaching 34.9 million worldwide, with liposuction remaining the most common surgical procedure at over 2.2 million cases. Consequently, the growing number of surgical procedures is fueling the expansion of the intravenous solutions market.

Major companies operating in the intravenous solutions market are concentrating on developing advanced syringes, such as pre-filled and ready-to-administer syringes, to secure a competitive advantage in the market. Pre-filled and ready-to-administer syringes come preloaded with medication and are designed for immediate use without the need for manual filling or preparation. For example, in August 2023, GENIXUS Corp., a US-based healthcare company, introduced KinetiXTM Rocuronium Bromide Injection in 5 mL and 10 mL ready-to-administer (RTA) syringes. The syringes are constructed from a transparent, durable polymer material that eliminates the risks associated with glass syringes. They are pre-filled and ready to administer, saving time and reducing medication errors. Rocuronium bromide injection is intended for intravenous use only and features several important attributes, including RFID-enabled with KitCheck, the latest kit and tray management technology, intuitive labeling, and a color-coded plunger rod to facilitate rapid identification.

Major companies operating in the intravenous solutions market are Pfizer Inc., Abbott Laboratories, Eli Lilly and Company, Fresenius SE & Co. KGaA, Becton, Dickinson and Company, Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., CSL Limited, B. Braun Melsungen AG, Grifols S.A., Terumo Corporation, Nipro Corporation, Sichuan Kelun Pharmaceutical Co. Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, ICU Medical Inc., Gland Pharma Limited, Cisen Pharmaceutical Co. Ltd., Amsino International Inc., JW Life Science Co. Ltd., Eurolife Healthcare Pvt. Ltd., Huaren Pharmaceutical Co. Ltd., Troikaa Pharmaceuticals Ltd., Claris Lifesciences Limited, Amanta Healthcare Ltd., Axa Parenterals Ltd., Wockhardt Ltd., Liqvor pharmaceuticals cjsc, Soxa Formulations & Research Pvt.Ltd., Aculife Healthcare Pvt. Ltd.

North America was the largest region in the intravenous solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intravenous solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the intravenous solutions market by increasing the cost of imported raw materials such as pharmaceutical-grade salts, glucose, amino acids, and sterile packaging components. These impacts are most evident in hospitals and home care settings, particularly in regions dependent on global supply chains such as north america and europe. Higher tariffs have raised manufacturing and procurement costs, leading to pricing pressures. However, they have also encouraged local production, capacity expansion, and supply chain diversification, supporting long-term resilience and availability.

The intravenous solutions market research report is one of a series of new reports that provides intravenous solutions market statistics, including intravenous solutions industry global market size, regional shares, competitors with a intravenous solutions market share, detailed intravenous solutions market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous solutions industry. This intravenous solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Intravenous solutions are sterile liquids administered directly into a patient’s bloodstream, commonly for hydration, medication delivery, or nutrient supplementation. They are employed in intravenous therapy to restore or maintain normal fluid volume and electrolyte balance when oral administration is not feasible.

The primary types of products included in intravenous solutions are total parenteral nutrition and peripheral parenteral nutrition. Total parenteral nutrition (TPN) delivers essential nutrients and fluids directly into the bloodstream for individuals who cannot eat or absorb nutrients through the digestive system. Various nutrients, including carbohydrates, vitamins and minerals, single-dose amino acids, parenteral lipid emulsion, and others, are utilized in several applications such as basic intravenous (IV) solutions, nutritional intravenous (IV) solutions, blood intravenous (IV) solutions, drug intravenous (IV) solutions, and irrigation intravenous (IV) solutions. Key end users include hospitals, clinics, ambulatory surgery centers, and home care settings.

The intravenous solutions market consists of sales of dextrose 5% in water (D5W), 0.45% sodium chloride (half normal saline), dextrose 5% in normal saline (D5NS), 0.2% sodium chloride (hypotonic saline), and dextrose 10% in water (D10W). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.